Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Situ Vaccination with Tremelimumab, Durvalumab, and Poly-ICLC in Advanced Cancers
NCT02643303Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Dec 2016
- Primary completion
- Feb 2022
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of poly iclc in solid tumor, head and neck squamous cell carcinoma (HNSCC), breast cancer, sarcoma, Merkel cell carcinoma (MCC), sponsored by Ludwig Cancer Research. Started Dec 2016; status: completed.
02
Drugs
poly iclc
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)breast cancersarcomaMerkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT02643303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643303.